Business
TELA Bio Reports First Quarter 2026 Financial Results
MALVERN, Pa., May 12, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA Bio”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial results for the first quarter ended March 31, 2026. Recent Highlights Announced strategic board refreshment plan to be effective at the conclusion of the 2026 Annual Meeting on June 9, 2026;Noted the U.S. commercial organization is fully staffed at planned 2026 levels;Delivered reve
About this update from Tela Bio, Inc.
[{"type":"image","alt":"TELA Bio, Inc.","displaySize":"","headline":null,"caption":"TELA Bio, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":81,"url":"https://media.zenfs.com/en/globenewswire.com/8d626409a8c31e4dc7fea09f34dc0ef7"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/7TF7cdHGILp3Xeeqsee8gQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTExMztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/8d626409a8c31e4dc7fea09f34dc0ef7","width":300,"height":81},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/7TF7cdHGILp3Xeeqsee8gQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTExMztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/8d626409a8c31e4dc7fea09f34dc0ef7","width":300,"height":81}},"lazy":false},{"type":"text","content":"MALVERN, Pa., May 12, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA Bio”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial results for the first quarter ended March 31, 2026.","length":268,"tagName":"p"},{"type":"text","content":"Recent Highlights","length":17,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Announced strategic board refreshment plan to be effective at the conclusion of the 2026 Annual Meeting on June 9, 2026;","length":120,"tagName":"p"}]},{"val":[{"type":"text","content":"Noted the U.S. commercial organization is fully staffed at planned 2026 levels;","length":79,"tagName":"p"}]},{"val":[{"type":"text","content":"Delivered revenue of $19.1 million in the first quarter of 2026, representing growth of 3% over the prior year period;","length":118,"tagName":"p"}]},{"val":[{"type":"text","content":"Accelerated European revenue growth to 41% over the prior year period, with continued momentum in the U.K. and early expansion into additional European markets;","length":160,"tagName":"p"}]},{"val":[{"type":"text","content":"Announced the U.S. commercial launch of OviTex LTR, providing a specialized, unique, and fully resorbable, tissue-based hernia repair solution; and","length":147,"tagName":"p"}]},{"val":[{"type":"text","content":"Reiterated full year 2026 revenue guidance of at least 8% growth over full year 2025.","length":85,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":709,"olType":false},{"type":"text","content":"“First quarter results reflect t...